Furthermore, recent publications provide proof of concept that chemical inhibition of ATGL might be a good therapeutic strategy for treating obesity and related metabolic diseases as mice treated with atglistatin showed reduced adipose tissue lipolysis, weight gain, and insulin resistance (60, 65, 66, 67). This evidence concerns the gene PNPLA2 and Insulin resistance.